Open AccessTreatment of Metastatic Extramammary Paget's Disease Associated With Adnexal Adenocarcinoma, With Anti‐HER2 Drugs Based on Genomic Alteration ERBB2 S310F
Author(s) -
Vornicova Olga,
Hershkovitz Dov,
YablonskiPeretz Tamar,
BenItzhak Ofer,
Keidar Zohar,
BarSela Gil
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0054
Subject(s) - medicine , extramammary paget's disease , apocrine , mutation , adenocarcinoma , paget disease , cancer research , disease , oncology , pathology , cancer , gene , genetics , biology
Extramammary Paget's disease is a rare intraepithelial malignant condition affecting the apocrine gland‐bearing skin. In this case, a genomic alteration, ERBB2 S310F mutation, was discovered. The ERBB2 S310F mutation seems to be a transforming mutation that should be targeted with anti‐HER2 drugs. Genomic tests are justified in rare tumors.